Rapamycin, known for its anti-aging properties, shows promise as a preventive strategy for Alzheimer’s disease (AD) in APOE4 carriers–the highest-risk group for late-onset AD. Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.